Opko Health (OPK) was Reiterated by Standpoint Research to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 18 from a previous price target of $16 . Standpoint Research advised their investors in a research report released on Jun 21, 2016.
Many Wall Street Analysts have commented on Opko Health. Standpoint Research Initiated Opko Health on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $16.Shares were Reiterated by Barrington Research on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $17 .
On the company’s financial health, Opko Health reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.03. The company had revenue of $291.00 million for the quarter, compared to analysts expectations of $266.30 million. The company’s revenue was up 866.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Opko Health opened for trading at $9.23 and hit $9.315 on the upside on Monday, eventually ending the session at $9.19, with a gain of 1.55% or 0.14 points. The heightened volatility saw the trading volume jump to 51,82,387 shares. Company has a market cap of $5,031 M.
In a different news, on Jun 21, 2016, Gamma Investments Trust Frost (CEO) purchased 10,000 shares at $9.19 per share price. According to the SEC, on May 17, 2016, Robert A Baron (director) sold 37,500 shares at $9.83 per share price. On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price, according to the Form-4 filing with the securities and exchange commission.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.